SEC Form 4 · accession 0000891293-16-000079
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Chief Business Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2016 | S | 1,600 | $1.195 | D | 618,484 | D | |
| Common Stock | Jan 4, 2016 | S | 1,898 | $1.20 | D | 616,586 | D | |
| Common Stock | Jan 4, 2016 | S | 800 | $1.205 | D | 615,786 | D | |
| Common Stock | Jan 4, 2016 | S | 1,900 | $1.21 | D | 613,886 | D | |
| Common Stock | Jan 4, 2016 | S | 1,700 | $1.22 | D | 612,186 | D | |
| Common Stock | Jan 4, 2016 | S | 800 | $1.23 | D | 611,386 | D | |
| Common Stock | Jan 4, 2016 | S | 300 | $1.235 | D | 611,086 | D | |
| Common Stock | Jan 4, 2016 | S | 202 | $1.24 | D | 610,884 | D | |
| Common Stock | Jan 4, 2016 | S | 600 | $1.25 | D | 610,284 | D | |
| Common Stock | Jan 4, 2016 | S | 200 | $1.26 | D | 610,084 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.